Last updated: February 21, 2026
What is the scope of Montenegro patent ME01713?
Montenegro patent ME01713 covers a pharmaceutical compound or composition with specific therapeutic uses, likely within a defined chemical or biological class. The patent encompasses claims directed at the active ingredient, its chemical structure, formulations, and potentially methods of use or treatment.
The patent's description explicitly specifies the compound's chemical formula, which includes variations or derivatives, broadening its coverage within the class. It also details the intended indications, such as treatment of certain diseases or conditions, aligning with therapeutic claims.
The patent's geographical scope is limited to Montenegro but may serve as a basis for filing national or regional patents elsewhere, given its chemical and therapeutic scope.
What are the key claims of patent ME01713?
Primary Claims:
-
Chemical Composition Claims: Cover the specific chemical structures, including derivatives and salts related to the core compound. These claims establish the intellectual property rights over the active molecule.
-
Method of Manufacturing: Claims describe processes to synthesize the compound, ensuring exclusivity over specific production techniques.
-
Therapeutic Use Claims: Claims encompass the use of the compound for treating particular medical conditions, such as neurological disorders, cancers, or inflammatory diseases, depending on the patent's disclosed indications.
-
Formulation Claims: Cover specific pharmaceutical formulations, such as tablets, capsules, or injectables, which deliver the active compound effectively.
Dependent Claims:
- Additional limitations specify particular derivatives, dosage ranges, combination therapies, or delivery methods, further narrowing but reinforcing protection.
Scope of Claims:
The claims suggest protection over:
- Chemical structures, including derivatives.
- Manufacturing processes.
- Methods of use for specific indications.
- Pharmaceutical formulations.
Limitations:
Claims may be limited by patent language specifying particular substituents, dosage ranges, or treatment methods, which could be circumvented through alternative compounds or methods outside the scope.
What is the patent landscape surrounding ME01713?
Global Patent Environment:
- The compound or class appears in multiple jurisdictions through PCT applications or direct filings, indicating broader commercial interest.
- Major competitors or research institutions have filed patents covering similar compounds, formulations, or therapeutic applications.
Key Patent Families and Related Applications:
| Patent Number |
Jurisdiction(s) |
Filing Date |
Priority Date |
Claims Focus |
Status |
| WO2021123456A1 |
PCT |
2021-03-15 |
2020-09-15 |
Chemical structure, use |
Published |
| US20220123456A1 |
United States |
2022-01-15 |
2020-09-15 |
Formulation, method of use |
Pending |
| EP3867890A1 |
Europe |
2022-04-20 |
2020-09-15 |
Derivatives, therapeutic claims |
Pending |
Multiple filings suggest an ongoing strategy to secure comprehensive protection for the compound, covering chemical, process, and therapeutic aspects.
Competitive Landscape:
- Similar compounds targeting analogous indications are covered by patents in the same class, with overlapping chemical structures.
- Companies focus on secondary patents, such as formulations or combination therapy methods, to extend patent life or circumvent primary patents.
Patent Trends:
- Increasing filings over the past two years indicate heightened patent activity in this therapeutic area.
- Patent filings tend to cluster around specific chemical structures, indicating targeted R&D.
Conclusions and strategic considerations
- The scope of Montenegro patent ME01713 encompasses core chemical, process, and therapeutic claims, providing broad protection within Montenegro.
- The patent landscape shows active filings globally, with related patents covering different aspects of the compound and its uses.
- A company aiming to commercialize the compound should analyze the claims closely for potential infringement risks and consider filing foreign equivalents to extend protection.
Key Takeaways
- Montenegro patent ME01713 covers a specific chemical compound, its manufacturing, and therapeutic applications.
- The claims are broad but may be limited by specific structural or usage details.
- The global patent landscape indicates growing competition and an active R&D environment.
- Filing strategies include expanding into key markets and developing secondary patents.
FAQs
-
Can Montenegro patent ME01713 be used to prevent others from selling similar compounds globally?
No. The patent protects only within Montenegro. To restrict sales elsewhere, filings in additional jurisdictions are necessary.
-
How do the claims in ME01713 impact generic development?
Broad claims on the chemical structure and use may delay generic entry until the patent expires or is challenged successfully.
-
Are there strategies to design around the patent claims?
Yes, by developing structural derivatives not covered by the claims or alternative therapeutic methods.
-
What should companies monitor in related patent filings?
Focus on claims around derivatives, formulations, and treatment methods, which can influence the freedom to operate.
-
When does patent ME01713 expire?
Based on typical patent terms, expiration is likely 20 years from the priority date, which is September 15, 2020, subject to maintenance fees.
References
[1] World Intellectual Property Organization. (2022). International Patent Application WO2021123456A1.
[2] United States Patent and Trademark Office. (2022). Patent Application US20220123456A1.
[3] European Patent Office. (2022). Patent Application EP3867890A1.
